Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP14 | P54578 | 11/20 | 1.00 |
| ▸ | USP7 | Q93009 | 3/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.97 |
| ▸ | HPGD | P15428 | 3/20 | 0.81 |
| ▸ | RAB9A | P51151 | 4/20 | 0.78 |
| ▸ | NPC1 | O15118 | 3/20 | 0.78 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.78 |
| ▸ | USP5 | P45974 | 2/20 | 0.78 |
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6922465 | 1.00 | USP14 (1.00) | USP14USP7SMN1; SMN2HPGDRAB9A | |
| SCHEMBL6921679 | 0.99 | SMN1; SMN2 (1.00) | USP14USP7SMN1; SMN2HPGDRAB9A | |
| SCHEMBL23524546 | 0.90 | USP14 (0.81) | USP14USP7SMN1; SMN2HPGDRAB9A | |
| SCHEMBL16079020 | 0.90 | SMN1; SMN2 (1.00) | USP14USP7SMN1; SMN2HPGDRAB9A | |
| SCHEMBL17949834 | 0.89 | SMN1; SMN2 (0.82) | USP14USP7SMN1; SMN2HPGDRAB9A | |
| SCHEMBL23524510 | 0.89 | SMN1; SMN2 (0.83) | USP14USP7SMN1; SMN2HPGDRAB9A | |
| SCHEMBL23524519 | 0.88 | SMN1; SMN2 (0.81) | USP14USP7SMN1; SMN2HPGDRAB9A | |
| SCHEMBL6922583 | 0.88 | SMN1; SMN2 (0.97) | USP14USP7SMN1; SMN2HPGDRAB9A | |
| SCHEMBL23524504 | 0.88 | USP14 (0.78) | USP14USP7SMN1; SMN2HPGDRAB9A | |
| SCHEMBL17949721 | 0.88 | USP14 (0.78) | USP14USP7SMN1; SMN2HPGDRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10351568-B2 | Compositions and methods for enhancing proteasome activity | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2019-07-16 | — | — | US | disclosed |
| US-20160214989-A1 | Compositions and Methods for Enhancing Proteasome Activity | THE ASSAY DEPOT, INC. | 2016-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10351568-B2 | Compositions and methods for enhancing proteasome activity | PSMG3, PSME3, PSMB11 | USP14 12/4885USP7 45/4885SMN1; SMN2 307/4885 |
| US-20160214989-A1 | Compositions and Methods for Enhancing Proteasome Activity | PSMG3, PSME3, PSMB11 | USP14 12/4885USP7 45/4885SMN1; SMN2 307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.